Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014

— Innovative cardiology solutions help deliver better care for more patients, respond to biggest challenges facing cardiologists

ANDOVER, Mass., Aug. 29, 2014 /PRNewswire/ – Royal Philips (NYSE: PHG AEX: PHIA) today announced its presence at the European Society of Cardiology (ESC) Congress 2014, where the company is highlighting the full range of its cardiology solutions serving clinicians and patients across the care continuum from prevention and diagnosis, to treatment, recovery and wellness. Visitors to the Philips booth (#F500) will experience Philips’ new Cardiology Solutions approach, enabling clinicians and health systems to deliver better cardiovascular care for more patients, at lower a cost, in the treatment of coronary artery disease, structural heart disease, and heart failure.

Photo – http://photos.prnewswire.com/prnh/20140828/141270
Photo – http://photos.prnewswire.com/prnh/20140828/141271
Photo – http://photos.prnewswire.com/prnh/20140828/141269
Photo – http://photos.prnewswire.com/prnh/20140828/141268
Photo – http://photos.prnewswire.com/prnh/20140122/NE50581LOGO

Philips Cardiology Solutions meet the needs of clinicians who are at the center of the cardiovascular care. Philips’ breadth of diagnostic and treatment solutions offer real-time tools to connect patient information with clinician knowledge, resulting in more personalized care, while innovations for recovery and wellness provide a safer transition from hospital to home.

“Interventional cardiology is continuously innovating new procedures to improve the lives of patients around the world,” said Gene Saragnese, CEO of Imaging Systems for Philips Healthcare. “Our cardiology solutions approach unlocks the data and insights necessary to improve efficiency in interventional cardiology, and together with our global customers and partners, we’re creating care delivery to optimally support clinicians and patients.”

One of the leading global conferences on cardiovascular care, the ESC Congress 2014 will showcase the industry’s most promising research and leading innovations. Throughout the event, Philips and physician partners will be participating in several symposia and presentations on topics including big data in cardiology and anatomical intelligence.

On Saturday, August 30th, Philips’ newest ultrasound system will make its worldwide debut, with an unveiling at the Philips Booth (#F500) at 4 p.m. CET.  Beginning August 30th  and running through September 3rd at the ESC Congress 2014, Philips will also offer demonstrations of its advanced imaging and ultrasound solutions designed for every step of the patient journey, including:

Screening and Diagnosis

  • ST80i ECG Stress Testing System – Manages patient information from start to finish through bi-directional network connectivity and turns stress ECG data into actionable insights.
  • Philips IntelliSpace ECG – A multi-modality, multi-vendor, scalable ECG management system, providing access to patient data for review of time-sensitive ECGs on a smartphone, to help improve patient care through comprehensive and flexible workflow management.
  • Xcelera Image Management System – Integrated, multi-modality image management system for cardiovascular information offering access to multiple applications within a single flexible workspace for use in multiple locations and across multi-sites.
  • IntelliSpace Portal with TAVI package – Quickly assesses the aortic root anatomy for pre-TAVI planning and obtains crucial information about eligibility, proper device size, and a recommendation for C-arm angle for device deployment.
  • EPIQ Ultrasound – Philips’ most powerful architecture ever applied to ultrasound imaging.

Treatment

  • Allura Clarity with ClarityIQ – Industry-leading interventional X-ray system offering high image quality at a low [X-ray] dose.
  • EchoNavigator R2 with Image Fusion – Fuses live X-ray and live echo for intuitive, live image guidance during structural heart disease procedures.
  • Hybrid OR – Provides the ability to seamlessly perform a wide range of open and minimally invasive procedures in a single room.
  • Heart Navigator – Supports structural heart disease procedures by simplifying planning, device and projection angle selection and providing live image guidance to support device positioning.

Recovery and Care Management

  • Q-Station, with anatomical intelligence tools – Streamlines ultrasound data management and performs advanced visualization, analysis and quantification of Philips echo data.
  • Motiva mobile – A content rich and interactive telehealth platform that is part of the Chronic Ambulatory Care program (eCAC), specifically designed to help empower chronically ill patients to effectively manage their disease state.

For more information on Philips presence at the ESC Congress 2014, please visit http://www.philips.com/esc, follow the #ESCcongress conversation @PhilipsHealth and continue the conversation via the Philips LinkedIn Innovations in Cardiology Group

For more information, please contact:
Kathy O’Reilly
Philips Healthcare
Tel: +1 978-659-2638
Mobile: +1 978-221-8919
Email: kathy.oreilly@philips.com
Twitter: @kathyoreilly

About Royal Philips:
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2013 sales of EUR 23.3 billion and employs approximately 113,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.

Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market

— Collaborations with academia and hospitals will be vital for development of multi-disciplinary technologies

KUALA LUMPUR, Malaysia, Aug. 27, 2014 /PRNewswire/ — Higher disposable incomes and the rapid penetration of health insurance are fuelling the demand for medical devices in Asia-Pacific. With the rise of medical tourism, the inflow of patients requiring medical and surgical intervention is further increasing. The market will continue its steady ascent as the region’s burgeoning population becomes increasingly vulnerable to age-related and non-communicable diseases, compelling significant investments in the domestic manufacturing of medical devices.

New analysis from Frost & Sullivan, 2014 Asia-Pacific Medical Devices Outlook, finds that the market earned revenues of US$53.13 billion in 2013 and estimates this to reach US$98.97 billion in 2018. The study, which analyses the opportunities, business models, medical device market revenues, and region-wise market, covers cardiac, orthopedic, wound care and wound closure, and minimally invasive surgery devices.

“The need for faster recovery, accuracy, and precision to ensure early discharge from hospitals will drive the development of new technology in medical device products,” said Frost & Sullivan Healthcare Consultant Poornima Srinivasan. “Manufacturers are also turning to frugal innovation, designing ‘as-is’ products to meet the needs of a domestic market burdened by rising healthcare costs.”

This is crucial as healthcare spending in most Asia-Pacific countries remains conservative, with tight budgets stalling consumer expenditure on expensive equipment. To counter this, manufacturers need to leverage proper distribution strategies and aggressively launch cost-effective yet high-quality, sustainable business products.

Contract manufacturing will become a common trend, since multinational products are exorbitantly priced and many governments have liberalized policies for domestic manufacturing. Partnering with ancillary services available in Asia-Pacific countries too could bring down the cost of products.

“As regional production gathers pace, and considering the multi-disciplinary nature of medical device technologies, industry integration with academia and hospitals is vital,” noted Srinivasan. “Such collaboration will aid technology transfer, improve competitiveness, and ultimately strengthen industry understanding of healthcare and services needs in the region.”

If you are interested in more information on this study, please send an e-mail to Donna Jeremiah, Corporate Communications, at djeremiah@frost.com, with your full name, company name, job title, telephone number, company e-mail address, company website, city, state and country.

2014 Asia-Pacific Medical Devices Outlook is part of the Advanced Medical Technologies (http://www.medtech.frost.com) Growth Partnership Service program. Frost & Sullivan’s related studies include: Global Emerging Interventional Cardiac Devices Market, Endoscopy Devices Market in Australia, South Korea, and Southeast Asia, and Image-guided Surgery and Robot-assisted Surgery Market in Asia-Pacific. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion
Join Us:           Join our community
Subscribe:       Newsletter on “the next big thing”
Register:         Gain access to visionary innovation

2014 Asia-Pacific Medical Devices Outlook
P7D5-54

Contact:
Donna Jeremiah
Corporate Communications – Asia Pacific
P: +61 (02) 8247 8927
F: +61 (02) 9252 8066
E: djeremiah@frost.com

Carrie Low
Corporate Communications – Asia Pacific
P: +603 6204 5910
F: +603 6201 7402
E: carrie.low@frost.com

Melissa Tan
Corporate Communications – Asia Pacific
P: +65 6890 0926
F: +65 6890 0999
E: melissa.tan@frost.com

http://www.frost.com

Leading Architectural Design Firm NBBJ Launches Healthcare Practice in China

SHANGHAI, Aug. 27, 2014 /PRNewswire/ — Global design and architecture firm NBBJ announced today the expansion of its healthcare planning and design services into China. Principal Rudy Widjaja will lead planning and design teams from NBBJ’s Shanghai office, where he will draw on his experience with healthcare clients in mainland China, Taiwan, Korea and the United States, as well as the firm’s global network of healthcare experts.  

The launch of NBBJ’s China healthcare practice comes at a time when the scope of the firm’s healthcare practice in Asia is increasing, with work for Shanghai Children’s Medical Center in mainland China; the Koo Foundation Sun Yat-Sen Cancer Center in Taipei, Taiwan; and the Samsung Medical Center in Seoul, Korea, among other projects.

Joan Saba, AIA, FACHA, Partner at NBBJ and the leader of its global healthcare practice, said: “We’ve successfully extended our innovative healthcare facilities concepts across the U.S., Europe and the Middle East. While we have long been serving select healthcare clients in China, we are very excited to deepen our practice by building a strong China team for future clients.”

“By formalizing our healthcare practice, we are now able to bring NBBJ’s renowned healthcare design expertise to our Chinese clients more readily. We can adapt best and future practices to the specific technical and cultural needs in China as new private healthcare models emerge,” added Principal Rudy Widjaja.  

For seventy years, NBBJ’s vision and compassion have helped shape many of the world’s most progressive academic medical centers, teaching hospitals, specialty hospitals, community hospitals, ambulatory care centers, medical office buildings and specialty facilities. NBBJ has worked with 11 of the top 17 U.S. News & World Report Honor Roll Hospitals. Clients include American University of Beirut Medical Center, Brigham and Women’s Hospital (a teaching affiliate of Harvard Medical School), Cambridge University, the Children’s Hospital of Philadelphia, Cleveland Clinic, Kaiser Permanente, the Kuwait Ministry of Health, Mayo Clinic, Massachusetts General Hospital, NYU Langone Medical Center, the Royal Liverpool University Hospital, the University of Pennsylvania Health System and Virginia Mason.

The firm successfully blends healing environments with efficient, evidence-based design and research. This approach has earned NBBJ notable accolades, including being named “Firm of the Year” and “Healthcare Architect of the Year” (for Joan Saba) by Healthcare Design and “Most Admired Healthcare Firm” by Interior Design for seven consecutive years. NBBJ is ranked as the second-largest healthcare architect in the world, according to BD World Architecture, and by Engineering News-Record as the “#1 Green Architecture Firm.” The firm has been the recipient of more than 300 healthcare design awards.

In the late 1990s, NBBJ formed a team to meet clients’ demand for services in a rapidly growing Asia market, which led to the opening of the Shanghai office in 2005. In China, NBBJ is currently designing corporate offices for Alipay in Hangzhou, Suning in Nanjing, Tencent in Shenzhen and WeChat in Guangzhou. Commercial mixed-use developments include Yanlord Landmark in Chengdu and Eton Place in Xiamen. Recent sports and convention centers include the Hangzhou Olympic Sports Center in Hangzhou, the Asia World Expo in Hong Kong and the Qingdao Aoshan Bay International Exhibition Center. The firm’s master planning work spans the country, from the waterfront redevelopment of the Shanghai Bund to the 25,000-hectare city master plan for Karamay. NBBJ is the recipient of multiple MIPIM Asia, Cityscape and ASLA awards for its work in China.

To celebrate the expansion of the Chinese healthcare practice, NBBJ Partners Joan Saba and Timothy Johnson as well as Principal Rudy Widjaja are hosting a salon event, “Healthy China: What’s Next for Healthcare and Cities,” which will take place at The Langham, Xintiandi Shanghai, September 15, 2014, from 6:00 to 9:00 pm.

The invitation-only salon is a platform for discussion and knowledge sharing among leaders, thinkers and builders of health practice and health facilities. The format for the evening will be a panel discussion moderated by the Editor-in-Chief of Forbes (China) magazine, Jiangong Zhou. Panelists include John Cai, Director, Centre for Healthcare Management and Policy, and Adjunct Professor of Economics, China Europe International Business School (CEIBS); Hongyang Wang, Professor, School of Architecture and Urban Planning, Nanjing University; Joseph D. Tucker, Director, UNC Project-China; and Joan Saba, Healthcare Design Partner, NBBJ.

For more information:
US: Helen Dimoff, Director of Communications, NBBJ, hdimoff@nbbj.com
China: Stella Ye, stella.ye@motto-consulting.com.cn

For more information on the event:
http://www.nbbj.com/news/2014/8/11/healthy-china-whats-next-for-healthcare-and-cities/

To request an invitation to the event:
Cindy Wu, cwu@nbbj.com

About NBBJ
NBBJ creates innovative places and experiences for organizations worldwide, and designs environments, communities and buildings that enhance people’s lives. Founded in 1943, NBBJ is an industry leader in healthcare and corporate facilities and has a strong presence in the commercial, civic, science, education and sports markets. The firm has won numerous awards and has been recognized as one of the world’s “Top Ten Most Innovative Architecture Firms” by Fast Company magazine. NBBJ has more than 750 employees in ten offices worldwide, including Beijing, Boston, Columbus, London, Los Angeles, New York, Pune, San Francisco, Seattle and Shanghai. Clients include Alibaba, Amazon, the Bill & Melinda Gates Foundation, Boeing, Cambridge University, Cleveland Clinic, GlaxoSmithKline, Google, Massachusetts General Hospital, Microsoft, Reebok, Salk Institute, Samsung, Stanford University, Starbucks, Telenor, Tencent and the Wellcome Trust.

http://www.nbbj.com

Frost & Sullivan: Multi-Modality Breast Imaging Systems Spur Innovations in Europe

– Vendors focus on multi-modality equipment that improves the efficiency, specificity and sensitivity of breast cancer screening

LONDON, Aug. 26, 2014 /PRNewswire/ — National population-based screening programs for asymptomatic women aged 40 and above have been established in many European countries for early detection of breast cancer. With every passing year, this population cohort is expanding, spurring breast cancer screening rates and fuelling the need for breast imaging systems. With the number of women being diagnosed with breast cancer also bound to increase, the adoption of equipment for procedures such as biopsy and image guidance too will grow.

Logo – http://photos.prnewswire.com/prnh/20140826/139581

New analysis from Frost & Sullivan, Analysis of the European Breast Imaging Systems Market, finds that the market earned revenues of $988.3 million in 2013 and estimates this to reach $1,384.2 million in 2020. The study covers x-ray mammography, breast ultrasound, breast magnetic resonance imaging (MRI), molecular breast imaging (MBI), and breast computer-aided detection (CAD).

While mammography has been considered the ‘gold standard’ for breast screening, adjunct technologies such as breast ultrasound, breast MRI and MBI too are gaining traction as they improve the standards of diagnosis and treatment of breast cancers.

“The European market will continue to evolve as breast imaging systems vendors look for innovative technologies to battle the increasing rate of false positives and overcome limitations while scanning women with dense breast tissue,” said Frost & Sullivan Healthcare Research Analyst Raghuraman Madanagopal. “3-D tomosynthesis, automated breast ultrasound and MBI are the results of such technological innovations that ensure maximum efficiency and minimum error rates.”

However, sporadic reimbursement trends across countries may lead to equally sporadic uptake of these advanced modalities for breast imaging. While the more commonly performed mammography and the less expensive ultrasound procedures are reimbursed sufficiently, the trend changes for costly procedures such as MRI and MBI.

To overcome this restraint, many breast imaging facilities in Europe are employing multi-modality screening. This, in turn, is expected to drive the use of supplementary modalities such as breast ultrasound.

“Research studies in recent years have validated the benefits that multi-modality screening provides over regular mammography screening, since one modality can overcome the limitations of another,” noted Madanagopal. “In accordance with this validation that a multi-modality approach improves the efficiency, specificity and sensitivity of breast cancer screening procedures, a wide product portfolio will be a core competitive factor in the European breast imaging systems market.”

If you are interested in more information on this study, please email Anna Zanchi, Corporate Communications, at anna.zanchi@frost.com

Analysis of the European Breast Imaging Systems Market is part of the Advanced Medical Technologies Growth Partnership Service program. Frost & Sullivan’s related studies include: US Nuclear Medicine and PET Imaging Systems Market, and European Ultrasound Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact
Anna Zanchi
Corporate Communications – Europe
P: +39.02.4851 6133
E: anna.zanchi@frost.com

http://www.frost.com

Logo – http://photos.prnasia.com/prnh/20140826/8521404802LOGO

Frost & Sullivan Applauds Volpara Solutions’ Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer

Volpara Solutions is the only company with a dose measurement tool specifically for breast imaging

MOUNTAIN VIEW, Calif., Aug. 26, 2014 /PRNewswire/ — Based on its recent analysis of the breast imaging solutions market, Frost & Sullivan recognizes Volpara Solutions with the 2014 North American Frost & Sullivan Award for Technology Innovation Leadership. Volpara Solutions offers an innovative range of volumetric breast imaging solutions for the early detection of breast cancer. Over the past few years, the company has steadily introduced several new solutions and has expanded its global reach to cover the United States, Europe, Asia and Australia.

Volpara’s suite of quantitative solutions includes VolparaDose, VolparaDensity, VolparaAnalytics and VolparaResearch. The Density and Dose solutions are patient-specific, while the Analytics and Research solutions are clinic-wide monitoring tools.

VolparaDensity automatically generates an objective measurement of volumetric breast density and a FDA-cleared BI-RADS breast density category, while VolparaDose helps keep track of patient-specific dose exposure. VolparaAnalytics assists in quality assurance by monitoring critical elements of the breast imaging process and generating key metrics to help understand the performance of technologists, readers, and mammography and tomosynthesis machines. VolparaResearch is aimed at research facilities that are looking to analyze large datasets of breast measurement information captured across time.

“Frost & Sullivan lauds Volpara Solutions for continuous leadership in technology innovation, thoughtfulness in identifying the unmet need for dose tracking in breast imaging, and a clear vision for what analytics can achieve in the early detection and treatment of breast cancer. Furthermore, all of the applications are built to serve across both full-field digital mammography and digital tomosynthesis systems, and with multi-vendor compatibility and reproducible data,” said Frost & Sullivan Research Director, Advanced Medical Technologies Group, Siddharth Saha. “This is of high relevance in the industry, as tomosynthesis is quickly gaining currency, with 30 percent of the members of the Society of Breast Imaging in the U.S. already using it.”

VolparaDose, along with VolparaAnalytics, gives radiologists patient-specific quantitative data to help minimize dose in mammography and tomosynthesis while maintaining image quality. While several market participants offer breast density measurement tools, Frost & Sullivan confirms that Volpara Solutions is the only company with a dose measurement tool specifically for breast imaging. It is necessary to measure volumetric breast density to control the dose, and Volpara Solutions has emerged as a pioneer in leveraging the Mega Trend of Dose Reduction by acknowledging patient-specific dose tracking and reporting as a white-space opportunity.

Furthermore, by enabling radiologists to track density and dose scores across time, Volpara Solutions helps support the movement toward the personalization of breast screening. Women with lower density have a lower risk of breast cancer, and researchers are looking at incorporating breast density into risk models that may support personalized screening protocols, which can include the best adjuvant imaging options for that woman (including breast tomosynthesis, automated whole breast ultrasound, molecular breast imaging, and breast MRI) as well as the frequency of screening.

“We are very proud to be recognized for the innovative solutions we have brought to the breast imaging market and for our vision and commitment to address unmet needs in the detection, prevention and treatment of breast cancer,” noted Ralph Highnam, Ph.D., Volpara Solutions’ CEO and chief scientist. “By allowing researchers across the globe to compare data to detect geographical, racial and age-related trends, we hope to take breast cancer research to the next level, which could lead to the development of predictive analytical models that will revolutionize early detection of breast cancer and save lives.”

Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend toward innovation, its relevance to the industry and the positive impact on brand perception.

Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for outstanding achievement in areas such as leadership, technological innovation, customer service, and product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research.

About Volpara Solutions

Founded to enable radiologists to give women the most accurate information possible regarding their breast health, Volpara Solutions is the wholly owned sales and marketing arm of Matakina Technology Limited of New Zealand. Matakina’s founders and Board of Directors include John Hood, Ph.D., former Vice Chancellor of the University of Oxford, UK; Ralph Highnam, Ph.D., former CEO of Mirada Solutions, one of the University of Oxford’s most successful spin-outs of recent times, and co-author of the seminal book Mammographic Image Analysis; and Professor Sir Michael Brady, a serial entrepreneur who recently retired from the University of Oxford, where he was Professor of Information Technology for 25 years.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on “the next big thing”

Register:        Gain access to visionary innovation

Contact:

Frost & Sullivan            

Volpara Solutions

Mireya Espinoza             

Chris Joseph

P: 210. 247.3870            

P: 510.339.2293

F: 210.348.1003             

E: chris.joseph@volparasolutions.com

E: mireya.espinoza@frost.com

 

 

Golden Meditech Announces the Disposal of Convertible Note Issued by CCBC for over US$88 million

HONG KONG, Aug. 25, 2014 /PRNewswire/ — Golden Meditech Holdings Limited (the “Company” or “Golden Meditech”, 801.HK; 910801.TW), a leading integrated healthcare enterprise in China, announced that it has entered into an agreement to sell its 7% senior convertible note due 2017 in an aggregate principal amount of US$50 million issued on 3 October 2012 by China Cord Blood Corporation (“CCBC”), a non-wholly-owned subsidiary of the Company (“Convertible Note”) to Magnum Opus International Holdings Limited (“Magnum”) and Cordlife Group Limited (“CGL”) for approximately US$88,090,000 (equivalent to approximately HK$682,697,500) in cash (the “Disposal”). Upon completion of the Disposal, each of Magnum and CGL will hold 50% of the Convertible Note.

Magnum is a private vehicle controlled by Mr. Kam Yuen, Chairman and Chief Executive Officer of the Company and Chairman of CCBC, and involves the CCBC management team. CGL is a cord blood banking services operator listed on the main board of the Singapore Exchange Securities Trading Limited, which currently owns approximately 10% of the issued shares of CCBC.

Following completion of the Disposal, Golden Meditech’s shareholding in CCBC will remain unchanged at approximately 42.0% and will only be diluted to approximately 33.9% if both Magnum and CGL exercise their rights to convert their Convertible Note into CCBC shares and, accordingly, their respective shareholdings in CCBC would increase by approximately 9.7%.

With mainland China’s healthcare sector continues to be driven by the government’s healthcare reform, Golden Meditech believes the Disposal would strengthen its financial position and liquidity, enhancing its ability to fund its potential acquisitions or expansion of its existing healthcare related businesses in mainland China.

The transaction is subject to Golden Meditech and CGL obtaining all relevant approvals and consents, including but not limited to the approval of Golden Meditech’s independent shareholders. An Extraordinary General Meeting (“EGM”) will be convened to consider and approve the transaction and a circular containing details of the Disposal and a notice of EGM are expected be dispatched to the shareholders no later than 16 September 2014.

About Golden Meditech Holdings Limited

Golden Meditech Holdings Limited (www.goldenmeditech.com) is China’s leading integrated-healthcare enterprise. Golden Meditech is a first-mover in China, having established dominant positions in medical devices and healthcare services markets, including cord blood stem cells storage and hospital management, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, the Group will continue to pursue a leading position in China’s healthcare industry both through organic growth and strategic expansion.